https://allsci.com/news/funding/ab-science-funding-als-trial-raises-eur-142m-to/ AllScien 2026-08-11T16:10:19.728899Z AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939 https://allsci.com/news/venture-financing/infinimmune-series-a-funding-raises-usd-75m-to/ AllScien 2026-08-11T14:24:30.715225Z Infinimmune raises USD 75m to bring IL-22 antibody into clinic https://allsci.com/news/venture-financing/epicrispr-series-c-funding-fshd-raises-usd-90m-to/ AllScien 2026-08-11T14:19:59.005073Z Epicrispr raises USD 90m to advance first-in-class epigenetic therapy into pivotal FSHD studies https://allsci.com/news/licensing-and-partnerships/oculis-privosegtor-acquisition-acquires-full/ AllScien 2026-08-11T14:14:22.102333Z Oculis rebuilds pipeline with Privosegtor buy from Accure https://allsci.com/news/funding/il-23-antagonist-funding-avere-raises-usd-500m-to/ AllScien 2026-08-11T13:52:56.568953Z Avere raises USD 500m for once-weekly IL-23R challenger to Icotyde https://allsci.com/news/funding/ipsc-neural-cell-therapy-funding-hopstem-secures/ AllScien 2026-08-11T13:42:42.931618Z China's Hopstem secures Series backing for iPSC neural cell therapy pipeline https://allsci.com/news/research/epigenetic-dna-repair-cancer-johns-hopkins/ AllScien 2026-08-11T13:29:30.543291Z Johns Hopkins probes macroH2A1 splicing as biomarker for PARP, TOP1 inhibitor response https://allsci.com/news/corporate-strategy/curium-abscint-acquisition-oncology-pet/ AllScien 2026-08-11T13:25:14.252226Z Curium continues to expand oncology PET pipeline with Abscint acquisition https://allsci.com/news/venture-financing/gene-therapy-funding-lifespan-vision-ventures/ AllScien 2026-08-11T13:16:21.018906Z Remedium Bio's obesity gene therapy platform picks up Lilly support in USD 10m Series A https://allsci.com/news/venture-financing/ai-drug-discovery-funding-aureka-closes-usd-100m/ AllScien 2026-08-11T13:07:54.905498Z Aureka closes USD 100m Series B to scale biological AI foundation models for drug discovery https://allsci.com/news/grants/ms-drug-screening-platform-artificial-axon-labs/ AllScien 2026-08-11T13:03:35.092823Z MIT spinout Artificial Axon gets NINDS backing for MS lesion-mimicking drug screening platform https://allsci.com/news/grants/velorum-nci-grant-lung-cancer-secures-126m-for/ AllScien 2026-08-11T12:58:51.910492Z Velorum secures NCI grant to advance heme-targeting lung cancer therapy to IND https://allsci.com/news/venture-financing/engasertib-phase-iii-trial-vaderis-raises-usd/ AllScien 2026-08-11T12:48:58.991600Z Vaderis raises USD 152m to advance engasertib into Phase III HHT trial https://allsci.com/news/research/nano-delivery-cancer-immunotherapy-university-of/ AllScien 2026-08-11T12:11:45.439348Z Michigan team develops oral metabolite drug to boost anti-PD-1 therapy https://allsci.com/news/research/cd19-car-t-cell-persistence-university-of/ AllScien 2026-08-11T10:58:17.772610Z UPenn researchers document decade-long CD19 CAR T cell persistence in Nature Medicine https://allsci.com/news/health/childhood-vaccine-recommendations-hhs/ AllScien 2026-08-11T08:54:12.425319Z Trump cuts US childhood vaccine schedule, targets MMR https://allsci.com/news/grants/universal-influenza-vaccine-scripps-research/ AllScien 2026-08-11T08:16:06.356238Z Scripps developing three-antigen nanoparticle platform for universal flu vaccine https://allsci.com/news/clinical-trials/sonelokimab-psoriatic-arthritis-hits-all/ AllScien 2026-08-11T07:59:40.633238Z MoonLake's sonelokimab meets all endpoints in Phase III psoriatic arthritis trial https://allsci.com/news/clinical-trials/divesiran-polycythemia-vera-silences-achieves-88/ AllScien 2026-08-11T07:46:49.459590Z Silence's divesiran achieves 88% response in Phase II PV trial with quarterly dosing https://allsci.com/news/clinical-trials/abcl635-hot-flashes-phase-ii-abcelleras-antibody/ AllScien 2026-08-11T07:13:49.979642Z AbCellera's NK3R antibody meets both endpoints in Phase II menopause study https://allsci.com/news/regulatory/fda-radiotherapy-drug-approval-blocks-itms-over/ AllScien 2026-08-10T18:15:51.265598Z FDA blocks ITM's radiotherapy drug over manufacturing defects, clinical data intact https://allsci.com/news/licensing-and-partnerships/ion-channel-drug-discovery-almirall-taps/ AllScien 2026-08-10T16:51:48.225522Z Almirall taps CrystalO's AI platform to discover ion channel drugs for skin disease https://allsci.com/news/licensing-and-partnerships/lacutamab-phase-iii-trial-sobi-funds-innates-with/ AllScien 2026-08-10T16:50:24.947417Z Sobi funds Innate's phase III lacutamab trial with USD 75 million upfront deal https://allsci.com/news/clinical-trials/sionna-cystic-fibrosis-drug-fails-sionnas-lead/ AllScien 2026-08-10T16:49:36.943623Z Sionna's lead cystic fibrosis program fails Phase IIa test, clouding NBD1 stabilizer strategy https://allsci.com/news/licensing-and-partnerships/novo-nordisk-aws-partnership-taps-as-preferred/ AllScien 2026-08-10T16:43:02.052703Z Novo Nordisk taps AWS as preferred cloud provider, launches London AI drug discovery hub https://allsci.com/news/clinical-trials/levosimendan-ph-hfpef-trial-tenaxs-misses-primary/ AllScien 2026-08-10T16:40:47.125973Z Tenax’s levosimendan fails Phase III LEVEL trial in PH-HFpEF https://allsci.com/news/funding/crispr-phase-i-trial-yale-receives-35m-nih/ AllScien 2026-08-10T16:20:33.945367Z NIH backs Yale's non-viral CRISPR platform for neurological gene editing https://allsci.com/news/licensing-and-partnerships/ras-inhibitor-partnership-asia-beone-and/ AllScien 2026-08-10T16:11:22.559105Z BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia https://allsci.com/news/regulatory/galleri-multi-cancer-blood-test-fda-convenes/ AllScien 2026-08-10T14:39:13.471542Z GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel https://allsci.com/news/research/immune-cells-aging-brain-stanford-researchers/ AllScien 2026-08-10T14:33:04.134141Z Stanford researchers uncover blood-to-brain immune cell migration in human aging https://allsci.com/news/research/mrsa-dna-polymerase-structure-acurx-maps-to/ AllScien 2026-08-10T14:22:58.608118Z Acurx and Leiden University Medical Center target first inhibitor-bound MRSA PolC structure https://allsci.com/news/pharma/jazz-pharmaceuticals-actio-acquisition-acquires/ AllScien 2026-08-10T13:57:16.933654Z Jazz moves on Actio Bio for up to USD 1.3b to enter KCNT1-driven epilepsy market https://allsci.com/news/policy/biotech-investments-china-screening-slotkin-and/ AllScien 2026-08-10T12:39:37.001935Z US bill could subject China-to-US pharma licensing deals to national security controls https://allsci.com/news/funding/ve303-phase-iii-trial-funding-vedanta-secures-usd/ AllScien 2026-08-10T12:28:17.675481Z Vedanta secures USD 60m ahead of Phase III VE303 recurrent C. difficile readout https://allsci.com/news/regulatory/fda-fast-track-designation-grand-pharmas/ AllScien 2026-08-10T11:04:13.855774Z Grand Pharma's FAP-targeted imaging agent earns FDA Fast Track designation https://allsci.com/news/clinical-trials/lz901-zoster-vaccine-efficacy-luzhus-shows-916/ AllScien 2026-08-10T10:58:09.589325Z Luzhu’s LZ901 shingles vaccine Phase III results published in Nature Communications https://allsci.com/news/clinical-trials/kras-g12d-inhibitor-nsclc-gfh375-becomes-first/ AllScien 2026-08-10T10:33:20.325252Z Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC https://allsci.com/news/regulatory/apitegromab-bla-fda-approval-scholar-rocks/ AllScien 2026-08-10T10:21:59.911628Z Scholar Rock shifts apitegromab BLA to second fill-finish site after Catalent FDA inspection https://allsci.com/news/licensing-and-partnerships/precision-oncology-biomarkers-hanchorbio-partners/ AllScien 2026-08-10T08:42:52.312673Z HanchorBio partners with Taiwan Cancer Moonshot to guide FBDB pipeline with multi-omics biomarkers https://allsci.com/news/research/ai-bacteriophages-e-coli-stanford-researchers-use/ AllScien 2026-08-10T08:39:37.581374Z Stanford researchers use Evo AI models to design novel bacteriophages against E. coli https://allsci.com/news/earnings-call-insights/beone-brukinsa-earnings-guidance-raises-full-year/ AllScien 2026-08-10T07:08:53.860167Z BeOne Q2'26: RAS-ON ADC unveiled as five solid tumor programs race toward Phase III